To clarify the effect of Nischarin on the biological behavior of hepatocellular carcinoma cells, two human hepatocellular carcinoma cell lines QGY-7701 and HepG2 were selected. The migration ability of the cells was determined with human normal hepatocyte LO2 as control. Western blotting was used to detect the differential expression of Nischarin and its downstream signals. The expression of Nischarin was knocked down by plasmid transfection to study the changes of cell migration ability, so as to evaluate the effect of Nischarin on hepatocellular carcinoma cells. The results of cell scratch experiment showed that compared with LO2 cells, the migration ability of HepG2 was significantly enhanced (P < 0.05), but there was no significant difference in the migration ability between QGY-7701 and LO2 cells. The results of Western blotting showed that the expression of Nischarin in HepG2 was significantly lower than that in LO2 cells (P < 0.05). Quantitative RT-PCR was used to detect the mRNA level of Nischarin in cells and found that the Nischarin mRNA level of HepG2 was significantly lower than that of LO2 (P < 0.01). When HepG2 cells were transfected with Nis-shRNA to knock down the expression of Nischarin, the cell migration ability was significantly increased (P < 0.05). While Nischarin overexpression significantly inhibited the phosphorylation of LIMK1 and cofilin, the important molecules of Rho-GTPase signaling pathway. These results strongly suggest that Nischarin is an endogenous protein with the ability to inhibit the migration of hepatocellular carcinoma cells. In conclusion, we found a protein that can inhibit the migration of hepatocellular carcinoma cells, which may have potential value in the diagnosis and treatment of hepatocellular carcinoma, but its molecular mechanism needs to be further studied.
| Published in | American Journal of Clinical and Experimental Medicine (Volume 10, Issue 3) |
| DOI | 10.11648/j.ajcem.20221003.14 |
| Page(s) | 83-87 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2022. Published by Science Publishing Group |
Nischarin, Hepatocellular Carcinoma, Migration
| [1] | McGlynn K, Petrick J, El-Serag H. Epidemiology of Hepatocellular Carcinoma [J]. Hepatology. 2021, 73 Suppl 1 (Suppl 1): 4-13. |
| [2] | Kulik L, El-Serag H. Epidemiology and Management of Hepatocellular Carcinoma [J]. Gastroenterology. 2019, 156 (2): 477-491. |
| [3] | Chang C, Wei W, Han D, et al. Expression of Nischarin negatively correlates with estrogen receptor and alters apoptosis, migration and invasion in human breast cancer [J]. Biochem Biophys Res Commun. 2017; 484 (3): 536-542. |
| [4] | Li J, He X, Dong R, et al. Frequent loss of NISCH promotes tumor proliferation and invasion in ovarian cancer via inhibiting the FAK signal pathway [J]. Molecular Cancer Therapeutics. 2015, 14 (5): 1202. |
| [5] | Ding Y, Zhang R, Zhang K, et al. Nischarin is differentially expressed in rat brain and regulates neuronal migration [J]. PLoS One. 2013; 8 (1): e54563. |
| [6] | Alahari S K, Lee J W, Juliano R L. Nischarin, a Novel Protein That Interacts with the Integrin α5 Subunit and Inhibits Cell Migration [J]. Journal of Cell Biology. 2000, 151 (6): 1141-54. |
| [7] | Ma Hao, Li Fei, Wu Ning, et al. Research Progress on Novel Protein Nischarin [J]. Chinese Pharmacology Bulletin. 2010, 26 (7): 844-847. |
| [8] | Zhao Taiyun, Wang Bo, Su Ruibin, et al. Bioinformatics Analysis and Preliminary Verification of New Gene Nischarin [J]. Advances in modern biomedicine. 2012, 12 (32): 6201-6206. |
| [9] | Ding Y, Milosavljevic T, Alahari SK. Nischarin inhibits LIM Kinase to regulate cofilin phosphorylation and cell invasion [J]. Mol Cell Biol. 2008, 28 (11): 3742-56. |
| [10] | Mitra AK, Sawada K, Tiwari P, et al. Ligand-independent activation of c-Met by fibronectin and α (5) β (1)-integrin regulates ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target [J]. Cancer Res. 2008, 68 (7): 2329-2339. |
| [11] | Cai YJ, Ma B, Wang ML, et al. Impact of Nischarin on EMT regulators in breast cancer cell lines [J]. Oncol Lett. 2020, 20 (6): 291. |
| [12] | McAndrews KM, Kalluri R. Nischarin Regulates Secretion of Exosomes and Cancer Progression [J]. Cancer Res. 2019, 79 (9): 2099-2101. |
| [13] | Dong S, Ruiz-Calderon B, Rathinam R, et al. Knockout model reveals the role of Nischarin in mammary gland development, breast tumorigenesis and response to metformin treatment [J]. Int J Cancer. 2020; 146 (9): 2576-2587. |
| [14] | Okpechi SC, Yousefi H, Nguyen K, et al. Role of Nischarin in the pathology of diseases: a special emphasis on breast cancer [J]. Oncogene. 2022; 41 (8): 1079-1086. |
| [15] | Maziveyi M, Dong S, Baranwal S, et al. Nischarin regulates focal adhesion and Invadopodia formation in breast cancer cells [J]. Mol Cancer. 2018, 17 (1): 21. |
APA Style
Guofen Zheng, Xuyi Lin, Bingwei Yu, Juncheng Yu, Xin Wang, et al. (2022). Effects of Nischarin on the Migration Ability of Hepatocellular Carcinoma Cells. American Journal of Clinical and Experimental Medicine, 10(3), 83-87. https://doi.org/10.11648/j.ajcem.20221003.14
ACS Style
Guofen Zheng; Xuyi Lin; Bingwei Yu; Juncheng Yu; Xin Wang, et al. Effects of Nischarin on the Migration Ability of Hepatocellular Carcinoma Cells. Am. J. Clin. Exp. Med. 2022, 10(3), 83-87. doi: 10.11648/j.ajcem.20221003.14
AMA Style
Guofen Zheng, Xuyi Lin, Bingwei Yu, Juncheng Yu, Xin Wang, et al. Effects of Nischarin on the Migration Ability of Hepatocellular Carcinoma Cells. Am J Clin Exp Med. 2022;10(3):83-87. doi: 10.11648/j.ajcem.20221003.14
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ajcem.20221003.14,
author = {Guofen Zheng and Xuyi Lin and Bingwei Yu and Juncheng Yu and Xin Wang and Aiqing Li and Yuemin Ding},
title = {Effects of Nischarin on the Migration Ability of Hepatocellular Carcinoma Cells},
journal = {American Journal of Clinical and Experimental Medicine},
volume = {10},
number = {3},
pages = {83-87},
doi = {10.11648/j.ajcem.20221003.14},
url = {https://doi.org/10.11648/j.ajcem.20221003.14},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajcem.20221003.14},
abstract = {To clarify the effect of Nischarin on the biological behavior of hepatocellular carcinoma cells, two human hepatocellular carcinoma cell lines QGY-7701 and HepG2 were selected. The migration ability of the cells was determined with human normal hepatocyte LO2 as control. Western blotting was used to detect the differential expression of Nischarin and its downstream signals. The expression of Nischarin was knocked down by plasmid transfection to study the changes of cell migration ability, so as to evaluate the effect of Nischarin on hepatocellular carcinoma cells. The results of cell scratch experiment showed that compared with LO2 cells, the migration ability of HepG2 was significantly enhanced (P P P P < 0.05). While Nischarin overexpression significantly inhibited the phosphorylation of LIMK1 and cofilin, the important molecules of Rho-GTPase signaling pathway. These results strongly suggest that Nischarin is an endogenous protein with the ability to inhibit the migration of hepatocellular carcinoma cells. In conclusion, we found a protein that can inhibit the migration of hepatocellular carcinoma cells, which may have potential value in the diagnosis and treatment of hepatocellular carcinoma, but its molecular mechanism needs to be further studied.},
year = {2022}
}
TY - JOUR T1 - Effects of Nischarin on the Migration Ability of Hepatocellular Carcinoma Cells AU - Guofen Zheng AU - Xuyi Lin AU - Bingwei Yu AU - Juncheng Yu AU - Xin Wang AU - Aiqing Li AU - Yuemin Ding Y1 - 2022/06/01 PY - 2022 N1 - https://doi.org/10.11648/j.ajcem.20221003.14 DO - 10.11648/j.ajcem.20221003.14 T2 - American Journal of Clinical and Experimental Medicine JF - American Journal of Clinical and Experimental Medicine JO - American Journal of Clinical and Experimental Medicine SP - 83 EP - 87 PB - Science Publishing Group SN - 2330-8133 UR - https://doi.org/10.11648/j.ajcem.20221003.14 AB - To clarify the effect of Nischarin on the biological behavior of hepatocellular carcinoma cells, two human hepatocellular carcinoma cell lines QGY-7701 and HepG2 were selected. The migration ability of the cells was determined with human normal hepatocyte LO2 as control. Western blotting was used to detect the differential expression of Nischarin and its downstream signals. The expression of Nischarin was knocked down by plasmid transfection to study the changes of cell migration ability, so as to evaluate the effect of Nischarin on hepatocellular carcinoma cells. The results of cell scratch experiment showed that compared with LO2 cells, the migration ability of HepG2 was significantly enhanced (P P P P < 0.05). While Nischarin overexpression significantly inhibited the phosphorylation of LIMK1 and cofilin, the important molecules of Rho-GTPase signaling pathway. These results strongly suggest that Nischarin is an endogenous protein with the ability to inhibit the migration of hepatocellular carcinoma cells. In conclusion, we found a protein that can inhibit the migration of hepatocellular carcinoma cells, which may have potential value in the diagnosis and treatment of hepatocellular carcinoma, but its molecular mechanism needs to be further studied. VL - 10 IS - 3 ER -
Information
Email: